Entero Healthcare Q1 FY27 Revenue Up 38.2% YoY

Revenue Performance:

Consolidated revenue grew 38.2% year-on-year to ₹1,940 crores.
On a like-for-like basis (adjusting for revenue recognized on a net margin basis and divestment of a subsidiary in the base period), growth was 40% year-on-year.
Organic revenue growth was 17.8% on a reported basis and 19.6% on a like-for-like basis.
The underlying pharmaceutical market growth was 13.8%, indicating the company significantly outpaced market growth.
Inorganic growth contributed 20.4%, entirely from the calendarization of acquisitions completed in the previous year. There were no new acquisitions during Q1 FY27.
A deliberate exit from certain low-margin businesses impacted reported growth by approximately 2.5%.

Profitability Metrics:

EBITDA margin expanded by 143 basis points year-on-year to 5.0%.
EBITDA grew 94% year-on-year.
Gross margin expanded by 147 basis points year-on-year to 11.4%.
Profit After Tax (PAT) was ₹52 crores, up 72% year-on-year, with a PAT margin of 2.7%.
Profit After Tax attributable to owners was ₹38 crores, up 37% year-on-year.
Non-controlling interest (minority interest) stood at ₹14 crores for the quarter (approximately 27% of profit before minority interest).

Margin Expansion Drivers:

The margin expansion was driven by three primary levers:

1. Scale-led procurement economies.

2. A growing share of revenue from the higher-margin MedTech business.

3. The deliberate exit from certain low-margin accounts.

Return Ratios and Capital Efficiency:

Return on Capital Employed (ROCE) improved significantly, nearly doubling year-on-year from 11.5% to 21.1%.
Return on Equity (ROE) improved from 9.0% to 20.4%.
Net working capital days improved to 61 days from 66 days a year ago.

Business Segments:

The MedTech segment is highlighted as a key structural lever for medium-term margin improvement.
MedTech revenue is on track to cross ₹1,000 crores in FY27 on an organic basis and carries higher gross and EBITDA margins than the core pharmaceutical distribution business.
The focus for the year is on deepening existing MedTech relationships and building organic capability.

Scale and Network:

The company now serves over 72,000 retail customers and more than 2,300 hospital customers.
It distributes over 83,400 SKUs and maintains relationships with more than 3,000 healthcare product manufacturers.
Operations are supported by 138 warehouses across 475 districts in 19 states.

M&A Strategy and Minority Interest:

The management's stated priority for FY27 is to consolidate, integrate, and organically build upon the platform created through significant M&A activity over the preceding two years. The company remains open to compelling opportunities, especially in the last quarter of the financial year.
The non-controlling interest (₹14 crores) relates to acquisitions where the company acquired a majority stake but not 100%. The company has pre-agreed, contractually defined call options (subject to certain conditions) to acquire the residual minority stake over a defined time horizon (2-5 years), exercisable at a valuation multiple consistent with the original acquisition.
The company retains full operational and cash flow control over these entities. The minority share of profit is reinvested in the business and not paid out.

FY27 Guidance Reaffirmed:

Consolidated revenue growth of approximately 23% year-on-year (excluding any contribution from new acquisitions).
EBITDA margin of 5%.
EBITDA to operating cash flow conversion of 50%.

Medium-Term Outlook (3-4 years):

The management believes the company can grow at an excess of 20% over the medium term, both organically and inorganically combined.
Targeting Return on Capital Employed (ROCE) in the range of 25% to 30% over this period.
Aspirational target for EBITDA margin is more than 6%.

Growth Strategy:

Growth is expected to be driven by increasing wallet share from existing customers and expanding the customer base, leveraging the company's value proposition as a one-stop shop with a wide product range and pan-India reach.
The company's unique value proposition for customers is product availability and service levels, while for principal companies, it is all-India access.

Interest Costs:

Interest cost increased quarter-on-quarter due to the full-quarter impact of debt (approx. ₹200 crores) taken for an acquisition disbursed at the end of January/early February. Interest costs are expected to remain broadly in the same range for the rest of the year.

Employee Costs:

Most of the impact from the annual increment cycle is effective from April 1st and is reflected in Q1. No major increase is expected for the rest of the year.

Depreciation:

The Q1 depreciation figure is considered the run-rate going forward, subject to any new major capex.

Tax Rate:

Working Capital & Cash Flow:

The 50% EBITDA to OCF conversion guidance is an annual figure due to seasonality (e.g., Q2 typically requires higher inventory). The company will continue to disclose quarterly working capital numbers.
Internal accruals (OCF) are expected to fund incremental working capital needs for 20%+ growth, and the surplus could be used for acquisitions, debt repayment, or buying out minorities, depending on what creates maximum shareholder value.

Small Acquisition:

A small acquisition was completed with Sai Pharma in Andhra Pradesh to build on the surgical consumable business profile. It was not a meaningful contributor to the overall size of the business.